Research Article
High SALM3 Expression in Tumor Cells and Fibroblasts Is Correlated with Poor Prognosis in Gastric Cancer Patients
Table 3
Association of SALM3 expression with clinicopathological characteristics in gastric cancer patients.
| | Characteristic | | SALM3 in tumor cells | SALM3 in fibroblasts | | SALM3- (%) | SALM3+ (%) | Pearson | | SALM3- (%) | SALM3+ (%) | Pearson | |
| | Total | 730 | | | | | | | | | | Age | | | | 0.233 | 0.629 | | | 1.054 | 0.305 | | >60 | 387 | 210 (54.3) | 177 (45.7) | | | 242 (62.5) | 145 (37.5) | | | | ≤60 | 343 | 180 (52.5) | 163 (47.5) | | | 227 (66.2) | 116 (33.8) | | | | Gender | | | | 0.236 | 0.627 | | | 0.031 | 0.860 | | Male | 537 | 284 (52.9) | 253 (47.1) | | | 344 (64.1) | 193 (35.9) | | | | Female | 193 | 106 (54.9) | 87 (45.1) | | | 125 (64.8) | 68 (35.2) | | | | Histological type | | | | 5.428 | 0.246 | | | 9.273 | 0.055 | | Tubular | 614 | 328 (53.4) | 286 (46.6) | | | 403 (65.6) | 211 (34.4) | | | | Mucinous | 31 | 21 (67.7) | 10 (32.3) | | | 14 (45.2) | 17 (54.8) | | | | Mixed (tubular and mucinous) | 16 | 7 (43.8) | 9 (56.3) | | | 7 (43.8) | 9 (56.3) | | | | Signet ring cell | 37 | 21 (56.8) | 16 (43.2) | | | 26 (70.3) | 11 (29.7) | | | | Othersa | 32 | 13 (40.6) | 19 (59.4) | | | 19 (59.4) | 13 (40.6) | | | | Differentiation | | | | 5.008 | 0.082 | | | 4.685 | 0.096 | | Well | 38 | 27 (71.1) | 11 (28.9) | | | 28 (73.7) | 10 (26.3) | | | | Middle | 193 | 101 (52.3) | 92 (47.7) | | | 133 (68.9) | 60 (31.1) | | | | Poor | 499 | 262 (52.5) | 237 (47.5) | | | 308 (61.7) | 191 (38.3) | | | | T | | | | 18.699 | <0.001 | | | 29.759 | <0.001 | | Tis | 41 | 30 (73.2) | 11 (26.8) | | | 36 (87.8) | 5 (12.2) | | | | T1+T2 | 220 | 136 (61.8) | 84 (38.2) | | | 164 (74.5) | 56 (25.5) | | | | T3+T4 | 469 | 224 (47.8) | 245 (52.2) | | | 269 (57.4) | 200 (42.6) | | | | N | | | | 9.958 | 0.019 | | | 73.214 | <0.001 | | N0 | 303 | 178 (58.7) | 125 (41.3) | | | 238 (78.5) | 65 (21.5) | | | | N1 | 135 | 72 (53.3) | 63 (46.7) | | | 97 (71.9) | 38 (28.1) | | | | N2 | 139 | 74 (53.2) | 65 (46.8) | | | 64 (46.0) | 75 (54.0) | | | | N3 | 153 | 66 (43.1) | 87 (56.9) | | | 70 (45.8) | 83 (54.2) | | | | M | | | | 8.139 | 0.004 | | | 2.453 | 0.117 | | M0 | 680 | 373 (54.9) | 307 (45.1) | | | 442 (65.0) | 238 (35.0) | | | | M1 | 50 | 17 (34.0) | 33 (66.0) | | | 27 (54.0) | 23 (46.0) | | | | TNM stage | | | | 19.053 | <0.001 | | | 72.728 | <0.001 | | 0+I | 184 | 120 (65.2) | 64 (34.8) | | | 149 (81.0) | 35 (19.0) | | | | II | 250 | 137 (54.8) | 113 (45.2) | | | 183 (73.2) | 67 (26.8) | | | | III+IV | 296 | 133 (44.9) | 163 (55.1) | | | 137 (46.3) | 159 (53.7) | | |
|
|
; aOthers: papillary adenocarcinoma, 5 cases; adenosquamous carcinoma, 6 cases; squamous cell carcinoma, 7 cases; undifferentiated carcinoma, 1 case; small cell malignant tumor, 9 cases; carcinoid, 2 cases; focal cancer, 2 cases. |
